ARTICLE | Finance

Anthera's test

February 15, 2010 8:00 AM UTC

The road show by cardiovascular and autoimmune play Anthera Pharmaceuticals Inc. will test the IPO market's appetite for companies with mid-stage product candidates. With Phase IIb data in hand for its lead candidate and $3.8 million cash, the company is preparing to go out the week of Feb. 22.

In the second quarter, the company hopes to start the Phase III VISTA-16 trial for lead candidate varespladib (A-002) to treat acute coronary syndrome (ACS)...